DelveInsight launched its new report on Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The key facts of the report:1. Among the European countries, Spain had the highest Myasthenia Gravis prevalence with around 15,275 cases, followed by Germany with about 12,400 cases in 2016.2. Japan had the lowest prevalent population of Myasthenia Gravis in 2016, with 14,985 cases.
Key benefits of the report:1. Myasthenia Gravis market report covers a descriptive overview and comprehensive insight of the Myasthenia Gravis epidemiology and Myasthenia Gravis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Myasthenia Gravis market report provides insights on the current and emerging therapies.3. Myasthenia Gravis market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Myasthenia Gravis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myasthenia Gravis market.
Request for a free sample report: https://www.delveinsight.com/sample-request/myasthenia-gravis-market
The key players in Myasthenia Gravis market are:1. UCB Pharma2. Novartis3. Argenx4. Ra Pharmaceuticalsand many others.
The launch of the emerging therapies is expected to significantly impact Myasthenia Gravis treatment scenario in the upcoming years:-Drugs covered1. Rozanolixizumab2. CFZ5333. Efgartigimod4. RA101495And many others
Table of contents:1. Key Insights2. Myasthenia Gravis Market Overview at a Glance3. Myasthenia Gravis Disease Overview4. Myasthenia Gravis Epidemiology and Patient Population5. Country Wise Myasthenia Gravis Epidemiology5.1. United States5.2. Germany5.3. France5.4. Italy5.5. Spain5.6. United Kingdom5.7. Japan6. Myasthenia Gravis Current Treatment Practices7. Unmet Needs8. Myasthenia Gravis Marketed drugs8.1. Key cross competition- Marketed drugs8.2. Mestinon: Valeant Pharmaceuticals8.3. Soliris: Alexion Pharmaceuticals8.4. Prograf: Astellas Pharma8.5. Venoglobulin IH: Mitsubishi Tanabe Pharma9. Myasthenia Gravis Emerging Therapies9.1. Key cross competition- Emerging Therapies9.2. Rozanolixizumab: UCB Pharma9.3. CFZ533: Novartis9.4. Efgartigimod : Argenx9.5. RA101495: Ra Pharmaceuticals9.6. Firdapse: Catalyst Pharmaceuticals9.7. Hizentra: CSL Behring9.8. IGIV-C: Grifols Therapeutics10. Myasthenia Gravis 7 Major Market Analysis11. Market Outlook by Country11.1. The United States: Market Outlook11.2. United States Market Size11.3. EU-5 Countries: Market Outlook11.4. Germany11.5. France11.6. Italy11.7. Spain11.8. United Kingdom11.9. Japan: Market Outlook12. Market Drivers13. Market Barriers14. Appendix15. DelveInsight Capabilities16. Disclaimer17. About DelveInsight
Related reports:
Myasthenia Gravis – Epidemiology Forecast to 2030
Myasthenia Gravis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/